Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity

No abstract is available for this paper.

• Publication year

  2015

• Venue

  HYPERTENSION

• Publication date

  2015-11-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1161/HYPERTENSIONAHA.115.06032PMID 26351031
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy.

  2015cited by this paper
• Left Ventricular Hypertrophy and Obesity: Only a Matter of Fat?

  2015cited by this paper
• Galectin‐3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin

  2015influential reference
• Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.

  2015cited by this paper
• Galectin-3 is expressed in the myocardium very early post-myocardial infarction.

  2015cited by this paper
• The role of blood pressure, body weight and fat distribution on left ventricular mass, diastolic function and cardiac geometry in children

  2015cited by this paper
• Mineralocorticoid Receptor Antagonism Treats Obesity-Associated Cardiac Diastolic Dysfunction

  2015cited by this paper
• Lack of Galectin-3 Prevents Cardiac Fibrosis and Effective Immune Responses in a Murine Model of Trypanosoma cruzi Infection.

  2015cited by this paper
• The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.

  2015cited by this paper
• Insulin resistance and subclinical abnormalities of global and regional left ventricular function in patients with aortic valve sclerosis

  2014cited by this paper
• The potential role of leptin in the vascular remodeling associated with obesity

  2014cited by this paper
• Impact of body mass index on left ventricular mass.

  2014cited by this paper
• Independent Influence of Overweight and Obesity on the Regression of Left Ventricular Hypertrophy in Hypertensive Patients

  2014cited by this paper
• Galectin-3: A Modifiable Risk Factor in Heart Failure

  2014cited by this paper
• Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity

  2014cited by this paper
• Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities.

  2014cited by this paper
• Oleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease.

  2014cited by this paper
• Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).

  2014influential reference
• Features of Cardiac Remodeling, Associated With Blood Pressure and Fibrosis Biomarkers, Are Frequent in Subjects With Abdominal Obesity

  2014cited by this paper
• Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.

  2013cited by this paper
• Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

  2013cited by this paper
• Cardiac Structure and Function and Insulin Resistance in Morbidly Obese Patients: Does Superobesity Play an Additional Role?

  2013cited by this paper
• Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade

  2013cited by this paper
• A Role for Soluble ST2 in Vascular Remodeling Associated with Obesity in Rats

  2013cited by this paper
• Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction

  2013cited by this paper
• Association of galectin‐3 and fibrosis markers with long‐term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE‐HF (Cardiac Resynchronization in Heart Failure) trial

  2012influential reference
• The fibrosis marker galectin‐3 and outcome in the general population

  2012cited by this paper
• Anatomical and Functional Alterations of the Heart in Morbid Obesity. Changes After Bariatric Surgery

  2012cited by this paper
• Modificaciones anatomofuncionales del corazon en la obesidad morbida. Cambios tras la cirugia bariatrica

  2012cited by this paper
• Anatomical and functional alterations of the heart in morbid obesity. Changes after bariatric surgery.

  2012cited by this paper
• Impact of obesity on cardiovascular disease.

  2011cited by this paper
• Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes.

  2010influential reference
• Recognition of galactan components of pectin by galectin‐3

  2009cited by this paper
• Modified citrus pectin anti-metastatic properties: one bullet, multiple targets.

  2009cited by this paper
• Galectin‐3: a novel mediator of heart failure development and progression

  2009cited by this paper
• Galectin-3 Is an Amplifier of Inflammation in Atherosclerotic Plaque Progression Through Macrophage Activation And Monocyte Chemoattraction

  2008cited by this paper
• Cardiac remodeling in obesity.

  2008cited by this paper
• Recommendations for chamber quantification.

  2006cited by this paper
• Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

  2006influential reference
• Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction

  2004cited by this paper
• Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats

  1998cited by this paper
• New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function--a study in normals and dilated cardiomyopathy.

  1995cited by this paper

• Pathology-tailored nanotherapy via Galectin-3-targeted and triple-responsive nanoparticles enables multimodal therapy against aortic dissection

  2026cites this paper
• Obesity-Associated Cardiac Fibrosis: Mechanisms and Emerging Therapeutic Targets

  2026influential citation
• Epicardial Fat and Heart Failure in Type 2 Diabetes: Metabolism, Imaging and Novel Biomarkers—A Translational Perspective

  2025cites this paper
• Pectin and Its Beneficial Effect on Health: New Contributions in Research and the Need to Increase Fruits and Vegetables Consumption—A Review

  2025cites this paper
• Modified Citrus Pectin (MCP) Confers a Renoprotective Effect on Early‐Stage Nephropathy in Type‐2 Diabetic Mice

  2024cites this paper
• Effect of modified citrus pectin on galectin-3 inhibition in cisplatin-induced cardiac and renal toxicity.

  2024cites this paper
• Galectin‐3, Metabolic Risk, and Incident Heart Failure: The ARIC Study

  2024cites this paper
• Screening and characterization of an anti-inflammatory pectic polysaccharide from Cucurbita moschata Duch.

  2024cites this paper
• The mechanisms underlying the cardiac effects of modified citrus pectin in obese rats with myocardial ischemia: Role of galectin-3.

  2024cites this paper
• Non-Sugar Sweetener Rubusoside Alleviates Lipid Metabolism Disorder In Vivo and In Vitro by Targeting PPARγ/α, Lgals3, and Mknk2.

  2024cites this paper
• Herbal Insights: Exploring the Therapeutic Potential of Indian Dietary Herbs in Diabetic Cardiomyopathy Management

  2024cites this paper
• The detrimental role of galectin‐3 and endoplasmic reticulum stress in the cardiac consequences of myocardial ischemia in the context of obesity

  2024cites this paper
• Proteomics couples electrical remodelling to inflammation in a murine model of heart failure with sinus node dysfunction

  2024cites this paper
• Value of NT-proBNP and Galectin-3 as Biomarkers in the Follow-Up of Asymptomatic Elderly Patients with Severe Aortic Stenosis

  2023cites this paper
• Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation.

  2023cites this paper
• Soluble ST2 as a New Oxidative Stress and Inflammation Marker in Metabolic Syndrome

  2023cites this paper
• Exploring the Mechanistic Link Between Obesity and Heart Failure

  2023cites this paper
• Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors

  2022cites this paper
• Human C-peptide is a ligand of the elastin-receptor-complex and therewith central to human vascular remodelling and disease in metabolic syndrome

  2022cites this paper
• Inhibition of Src improves cardiac fibrosis in AngII-induced hypertrophy by regulating the expression of galectin-3.

  2022cites this paper
• The emerging role of leptin in obesity-associated cardiac fibrosis: evidence and mechanism

  2022cites this paper
• Importance of cardiac imaging assessment of epicardial adipose tissue after a first episode of myocardial infarction

  2022cites this paper
• Obesity, Galectin‐3, and Incident Heart Failure: The ARIC Study

  2022cites this paper
• The role of lipotoxicity in cardiovascular disease

  2022cites this paper
• Galectin-3 Inhibition Ameliorates Streptozotocin-Induced Diabetic Cardiomyopathy in Mice

  2022cites this paper
• Oxidative Stress and Vascular Damage in the Context of Obesity: The Hidden Guest

  2021cites this paper
• Oxidative Stress and Vascular Damage in the Context of Obesity : The Hidden

  2021cites this paper
• Pectins from various sources inhibit galectin-3-related cardiac fibrosis.

  2021cites this paper
• Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial

  2021cites this paper
• Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein

  2021cites this paper
• PDGF-D activation by macrophage-derived uPA promotes AngII-induced cardiac remodeling in obese mice

  2021cites this paper
• Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?

  2021cites this paper
• Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current Knowledge

  2021cites this paper
• The Interplay of Mitochondrial Oxidative Stress and Endoplasmic Reticulum Stress in Cardiovascular Fibrosis in Obese Rats

  2021cites this paper
• Microsomal prostaglandin E synthase‐1 is involved in the metabolic and cardiovascular alterations associated with obesity

  2021cites this paper
• Endoplasmic Reticulum-Mitochondria Contacts: A Potential Therapy Target for Cardiovascular Remodeling-Associated Diseases

  2021cites this paper
• Galectin-3 mediates high-glucose-induced cardiomyocyte injury by NADPH oxidase/reactive oxygen species pathway.

  2020cites this paper
• SIRT3 Ablation Deteriorates Obesity-Related Cardiac Remodeling by Modulating ROS-NF-κB-MCP-1 Signaling Pathway.

  2020cites this paper
• Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

  2020cites this paper
• Structural features and anti-inflammatory properties of pectic polysaccharides: A review

  2020cites this paper
• Letter to the Editor: Not all modified citrus pectins are the same: size does matter.

  2019cites this paper
• Galectin-Carbohydrate Interactions in Biomedicine and Biotechnology.

  2019cites this paper
• β‐Adrenoceptor activation affects galectin‐3 as a biomarker and therapeutic target in heart disease

  2019cites this paper
• Galectin‐3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients

  2019cites this paper
• Circulating factors in heart failure

  2019cites this paper
• Fibroblast growth factor 21 protects against pathological cardiac remodeling by modulating galectin‐3 expression

  2019cites this paper
• Soluble ST2 promotes oxidative stress and inflammation in cardiac fibroblasts: An in vitro and in vivo study in aortic stenosis.

  2019cites this paper
• [Galectin-3 as a novel biotarget in cardiovascular alterations associated to development of severe aortic stenosis].

  2019cites this paper
• Berberine inhibits adipocyte differentiation, proliferation and adiposity through down-regulating galectin-3

  2019cites this paper
• Aldosterone/Mineralocorticoid Receptor Downstream Targets as Novel Therapeutic Targets to Prevent Cardiovascular Remodeling

  2019cites this paper
• Mineralocorticoid Receptor and Leptin: A Dangerous Liaison in the Obese Heart

  2019cites this paper
• Rethinking the impact of RG-I mainly from fruits and vegetables on dietary health

  2019cites this paper
• Pleiotropic Effects of Modified Citrus Pectin

  2019influential citation
• The obesity phenotypes: emerging role of cardiac biomarkers

  2018cites this paper
• The Role of Galectins as Modulators of Metabolism and Inflammation

  2018cites this paper
• Upregulated galectin-3 is not a critical disease mediator of cardiomyopathy induced by β2-adrenoceptor overexpression.

  2018influential citation
• Galectin-3 in the pathogenesis of heart failure: a causative mediator or simply a biomarker?

  2018cites this paper
• Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage.

  2018cites this paper
• Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update

  2018cites this paper
• Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity

  2018cites this paper
• Novel heart failure biomarkers: why do we fail to exploit their potential?

  2018cites this paper
• Investigation of galectin-3 levels in diabetic foot ulcers.

  2018cites this paper
• Echocardiographic diastolic function evolution in patients with an anterior Q‐wave myocardial infarction: insights from the REVE‐2 study

  2018cites this paper
• Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats

  2018cites this paper
• Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease

  2018cites this paper
• Can biomarker predict development and progression of pulmonary artery hypertension?

  2017cites this paper
• The role of oxidative stress in the crosstalk between leptin and mineralocorticoid receptor in the cardiac fibrosis associated with obesity

  2017cites this paper
• University of Groningen Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease

  2017cites this paper
• Can Biomarkers be Useful for Cardiovascular Risk Assessment in Patients with Different Phenotypes of Obesity

  2017cites this paper
• Cardiovascular biomarkers and obesity : interact with risk stratification ?

  2017cites this paper
• The impact of obesity in the cardiac lipidome and its consequences in the cardiac damage observed in obese rats.

  2017cites this paper
• Role of galectin-3 in autoimmune and non-autoimmune nephropathies.

  2017cites this paper
• Synergistic Antioxidant and Anti-Inflammatory Effects between Modified Citrus Pectin and Honokiol

  2017cites this paper
• A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis.

  2017cites this paper
• Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload Model

  2017cites this paper
• Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND.

  2016cites this paper
• Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage

  2016cites this paper
• Vascular Mineralocorticoid Receptors: Linking Risk Factors, Hypertension, and Heart Disease.

  2016cites this paper
• Role for Galectin‐3 in Calcific Aortic Valve Stenosis

  2016cites this paper
• Relationship of galectin-3 with obesity, IL-6, and CRP in women

  2016cites this paper
• Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression?

  2016cites this paper
• Achim Lother and Lutz Hein Disease Vascular Mineralocorticoid Receptors : Linking Risk Factors , Hypertension , and Heart

  2016cites this paper
• Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans*

  2016cites this paper
• Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression?

  2016cites this paper
• Galectin-3 in Obesity and Endotoxin-Induced Inflammation

  2016cites this paper